Drugs / N6022
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01746784 | Feb → Apr 2014 | cystic fibrosis | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01147406 | Aug 2010 → Jun 2011 | — | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT01316315 | Mar → Nov 2011 | asthma | Nivalis Therapeutics, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01339897 Comparator | Apr → Aug 2011 | — | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N6022 | “An exploratory proof of concept clinical study of N6022 in mild asthma to determine the potential bronchoprotective effects of GSNOR inhibition.” PMID 29642282 ↗ Apr 2018 |
| Action | Inhibit | “Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.” PMID 29642282 ↗ Apr 20181“Alcohol dehydrogenase class III inhibitor” CHEMBL1738699 ↗ |
| Modality | Small molecule | — CHEMBL1738699 ↗ |
| Route | Intravenous | “A 5 mg single dose given intravenously via syringe pump over 1 minute.” NCT01316315 ↗ |
| Target | ADH5 | “Alcohol dehydrogenase class III inhibitor” CHEMBL1738699 ↗ |